Experimental vaccine used in Ebola exposure case

March 27, 2009 By MELISSA EDDY and MIKE STOBBE , Associated Press Writers
In this Oct. 2007 photo provided by the Hamburg University hospital (UKE) on March 17, 2009 a quarantine unit at the hospital is shown during a disaster control exercise. Hours after a 45-year-old scientist accidentally pricked her finger with a needle used for injecting the Ebola virus into mice, leading members of the tight research community huddled over a trans-Atlantic telephone conference to plot a course of action. Within 24 hours of the March 12 accident, an experimental vaccine that had never before been tried on humans was on its way via international courier from a lab in Canada to Germany. The patient was treated in the pictured quarantine unit. (AP Photo/UKE, Jochen Koppelmeyer)

(AP) -- It was a nightmare scenario: A scientist accidentally pricked her finger with a needle used to inject the deadly Ebola virus into lab mice. Within hours, members of a tightly bound, yet far-flung community of virologists, biologists and others were tensely gathered in a trans-Atlantic telephone conference trying to map out a way to save her life.

Less than 24 hours later, an experimental - never before tried on humans - was on its way to Germany from a lab in Canada.

And within 48 hours of the March 12 accident, the at-risk scientist, a 45-year-old woman whose identity has not been revealed, was injected with the vaccine.

So far, so good. If the woman is still healthy by Thursday, she can consider herself safe.

Ebola hemorrhagic fever, seen mostly only in Africa, is one of the world's most feared diseases. It begins with flu-like symptoms, followed by bloody diarrhea and vomiting. Days later, some victims begin bleeding through the nose, mouth and eyes. Depending on the strain of virus, it can kill up to 90 percent of victims.

There is no cure. The virus is spread through direct contact with the blood or secretions of an infected person.

Dr. Stephan Guenther, head of the Bernhard Nocht Institute for Tropical Medicine in Hamburg, where the researcher was working, said tests so far show the scientist is healthy and free of the virus.

The peak period for an outbreak during the 21-day Ebola incubation period passed this week, he said.

"We are now on the downside," Guenther told The Associated Press, noting that with each passing day the chance of infection taking root diminishes.

It's not entirely clear the researcher was actually infected with the virus. At the time of the accident, she was wearing three layers of protective gloves, and though the needle stuck her, the plunger of the syringe was not pushed so it's not certain the virus entered her bloodstream.

That means scientists may never know if the vaccine worked or she was just lucky.

There are two other known accidents involving researchers who came into direct contact with a similar strain of Ebola. A Russian researcher died, and a British scientist became ill but survived.

After the needle stick, Guenther knew he had to act swiftly.

He rushed an e-mail to fellow scientists in the Ebola research community. One was Dr. Heinz Feldmann, chief of the virology laboratory at the Rocky Mountain Laboratories, a U.S. National Institutes of Health research facility in Hamilton, Mont.

"We considered this as serious as (the Russian) case, in terms of the exposure," Feldmann told the AP in a telephone interview last weekend.

Feldmann was part of an international group of experts from the U.S. Centers for Disease Control and Prevention, the U.S. Army Medical Research Institute of Infectious Diseases, the Canadian Public Health Agency, Boston University and the University of Texas Medical Branch.

Feldmann, Guenther and several other experts took part in the teleconference debating the options. These included a live vaccine never before tried on humans, another treatment designed to interfere with the virus' ability to multiply, or an anticoagulant that Army research found had saved the lives of monkeys exposed to Ebola.

The option that emerged as the strongest was the vaccine, which had been developed by Feldmann and collaborating researchers at several institutions. Much of the key work was done about nine years ago at a microbiology research lab run by the Canadian government in Winnipeg, Manitoba, where Feldmann worked at the time.

Although the vaccine is based on a different kind of virus, researchers used genetic engineering to make the virus look like Ebola, triggering an immune system response.

In a 2008 study, Feldmann and other researchers showed that when given 20 minutes after a lethal dose of Ebola virus, four of eight monkeys survived. There were no side effects, Feldmann said.

"The group came very swiftly to agreement that this vaccine would be the best ... because it had showed an effectiveness when used after exposure," Guenther said.

In the end, the scientist whose life was at risk made the decision herself. She took the vaccine about 48 hours after the accident. Within 12 hours, she had a headache, muscle pain and a fever, but recovered quickly.

"Those are normal reactions to live attenuated vaccines," Feldmann said.

While future study of the woman's immune response may help to clarify whether the vaccine saved her life or she was never infected with Ebola in the first place, it will most likely remain open to interpretation.

Either way, Feldmann said scientists cannot draw conclusions about the experimental vaccine's safety or effectiveness.

There's a long history of researchers testing vaccines on themselves or people close to them. Edward Jenner, the English physician who first invented a smallpox vaccine, included his own son among the children he first gave the immunization. And Jonas Salk, an inventor of polio vaccine, reportedly gave the vaccine to himself and his entire family before making it public.

This case is somewhat different. Using the experimental vaccine, "was to save her life, that was the priority," Feldmann said. It might have been five years or more before it was tried on humans because of additional animal studies and production issues, he added.

Guenther expressed hope the case would attract funding for more research in the field of such vaccines.

"Of course, we can't just go to Africa, now that we have seen such a vaccine went well when used on a human," Guenther said.

"Perhaps this will be like a little push, where one says, yes, it's possible. Everything that we are doing on an experimental level can actually be put into practice."


AP Medical Writer Mike Stobbe reported from Atlanta and Melissa Eddy contributed from Berlin.
©2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Related Stories

Recommended for you

Drug therapy from lethal bacteria could reduce kidney transplant rejection

August 3, 2017
An experimental treatment derived from a potentially deadly microorganism may provide lifesaving help for kidney transplant patients, according to an international study led by investigators at Cedars-Sinai.

Exploring the potential of human echolocation

June 25, 2017
People who are visually impaired will often use a cane to feel out their surroundings. With training and practice, people can learn to use the pitch, loudness and timbre of echoes from the cane or other sounds to navigate ...

Team eradicates hepatitis C in 10 patients following lifesaving transplants from infected donors

April 30, 2017
Ten patients at Penn Medicine have been cured of the Hepatitis C virus (HCV) following lifesaving kidney transplants from deceased donors who were infected with the disease. The findings point to new strategies for increasing ...

'bench to bedside to bench': Scientists call for closer basic-clinical collaborations

March 24, 2017
In the era of genome sequencing, it's time to update the old "bench-to-bedside" shorthand for how basic research discoveries inform clinical practice, researchers from The Jackson Laboratory (JAX), National Human Genome Research ...

The ethics of tracking athletes' biometric data

January 18, 2017
(Medical Xpress)—Whether it is a FitBit or a heart rate monitor, biometric technologies have become household devices. Professional sports leagues use some of the most technologically advanced biodata tracking systems to ...

Financial ties between researchers and drug industry linked to positive trial results

January 18, 2017
Financial ties between researchers and companies that make the drugs they are studying are independently associated with positive trial results, suggesting bias in the evidence base, concludes a study published by The BMJ ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

not rated yet Mar 28, 2009
Edward Jenner's son dead at 20 from Alzheimer's disease. Edward Jenner's nephew has smallpox vaccination too, was very feeble child and dead at 20 from TB. See Razzel P. "Edward Jenner's Cowpox Vaccine: The History of a Medical Myth." and Cook G. %u0421. "Charles Creighton (1847-1927): eminent medical historian but vehement anti-Jennerian."

Jonas Salk shot himself clear water, and 3 vaccinated members of his family dead from cancer at 3-5 years after vaccination. Official medicine passes over in silence those facts.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.